Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
CaMKIIδ-mediated inflammatory gene expression and inflammasome activation in cardiomyocytes initiate inflammation and induce fibrosis
Andrew Willeford, … , Shigeki Miyamoto, Joan Heller Brown
Andrew Willeford, … , Shigeki Miyamoto, Joan Heller Brown
Published June 21, 2018
Citation Information: JCI Insight. 2018;3(12):e97054. https://doi.org/10.1172/jci.insight.97054.
View: Text | PDF
Research Article Cardiology Inflammation

CaMKIIδ-mediated inflammatory gene expression and inflammasome activation in cardiomyocytes initiate inflammation and induce fibrosis

  • Text
  • PDF
Abstract

Inflammation accompanies heart failure and is a mediator of cardiac fibrosis. CaMKIIδ plays an essential role in adverse remodeling and decompensation to heart failure. We postulated that inflammation is the mechanism by which CaMKIIδ contributes to adverse remodeling in response to nonischemic interventions. We demonstrate that deletion of CaMKIIδ in the cardiomyocyte (CKO) significantly attenuates activation of NF-κB, expression of inflammatory chemokines and cytokines, and macrophage accumulation induced by angiotensin II (Ang II) infusion. The inflammasome was activated by Ang II, and this response was also diminished in CKO mice. These events occurred prior to any evidence of Ang II–induced cell death. In addition, CaMKII-dependent inflammatory gene expression and inflammasome priming were observed as early as the third hour of infusion, a time point at which macrophage recruitment was not evident. Inhibition of either the inflammasome or monocyte chemoattractant protein 1 (MCP1) signaling attenuated macrophage accumulation, and these interventions, like cardiomyocyte CaMKIIδ deletion, diminished the fibrotic response to Ang II. Thus, activation of CaMKIIδ in the cardiomyocyte represents what we believe to be a novel mechanism for initiating inflammasome activation and an inflammatory gene program that leads to macrophage recruitment and ultimately to development of fibrosis.

Authors

Andrew Willeford, Takeshi Suetomi, Audrey Nickle, Hal M. Hoffman, Shigeki Miyamoto, Joan Heller Brown

×

Figure 8

Inflammasome inhibition and NLRP3 gene deletion attenuate Ang II–induced inflammatory responses in the heart.

Options: View larger image (or click on image) Download as PowerPoint
Inflammasome inhibition and NLRP3 gene deletion attenuate Ang II–induced...
(A) Representative images and quantitation of cardiac cryosections stained with antibody to CD68 taken from mice infused with saline (vehicle [Veh]) or Ang II (1.5 μg/kg/min) for 1 day and injected intraperitoneally with saline (–) or 10 mg/kg MCC950 (MCC) every 12 hours starting 1 hour prior to infusion (n = 3–4/group). (B) Representative images and quantitation of cardiac cryosections stained with antibody to CD68 from WT or Nlrp3–/– (NLRP3 KO) mice infused with saline (Veh) or Ang II (1.5 μg/kg/min) for 1 day (n = 3/group). (C) mRNA expression of monocyte chemoattractant protein 1 (Ccl2/MCP1), macrophage inflammatory protein 1α (Ccl3/MIP1α), CXC motif ligand 1 (Cxcl1), CXC motif ligand 2 (Cxcl2), and IL-6 (Il6) in ventricles of control mice infused with saline or Ang II and injected with MCC950 as described above (n = 3–4/group). Two-way ANOVA was used for all comparisons. *P < 0.05 vs. Veh or MCC; **P < 0.01 vs. Veh; #P < 0.05, Ang II vs. Ang II + MCC or WT Ang II vs. NLRP3 KO Ang II. Scale bars: 50 μm.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts